Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiquimod Gel (0.06%) in Nodular Basal Cell Carcinoma
NCT01808950Phase 2Terminated
- Sponsor
- Spirig Pharma
- Start
- Feb 2013
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of resiquimod in basal cell carcinoma (nodular) (BCC), sponsored by Spirig Pharma. Started Feb 2013; status: terminated.
02
Drugs
resiquimod
03
Conditions
basal cell carcinoma (nodular) (BCC)
Beyond the preview
Go deeper on NCT01808950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01808950.